Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR …
F Chen, N Chen, Y Yu, J Cui - Frontiers in Oncology, 2020 - frontiersin.org
Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer …
It is controversial whether there is efficacy or safety benefit of epidermal growth factor
receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non-small cell …
receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non-small cell …
[HTML][HTML] Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or …
Y Chen, S Wen, Y Wu, L Shi, X Xu, B Shen - Critical Reviews in Oncology …, 2021 - Elsevier
Objective We conducted a meta-analysis to synthesize the results of published randomized
controlled trials conducted to evaluate the efficacy and safety of epidermal growth factor …
controlled trials conducted to evaluate the efficacy and safety of epidermal growth factor …
First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis
H Zhang, J Chen, T Liu, J Dang, G Li - PLoS One, 2019 - journals.plos.org
Background It remains unknown which is the optimal first-line treatment regimen for patients
with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer …
with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer …
First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review …
Q Wu, W Luo, W Li, T Wang, L Huang, F Xu - Frontiers in Oncology, 2021 - frontiersin.org
Objective The aim of this meta-analysis was to evaluate efficacy and toxicity of epidermal
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with …
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with …
[HTML][HTML] Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line …
E Bria, M Milella, F Cuppone, S Novello, A Ceribelli… - Annals of oncology, 2011 - Elsevier
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
[HTML][HTML] Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - Lung Cancer, 2021 - Elsevier
Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
Therapeutic efficacy comparison of 5 major EGFR-TKIs in advanced EGFR-positive Non–Small-cell lung cancer: a network meta-analysis based on head-to-head …
Y Zhang, Z Zhang, X Huang, S Kang, G Chen, M Wu… - Clinical Lung Cancer, 2017 - Elsevier
Background Five major first-and second-generation epidermal growth factor receptor-
tyrosine kinase inhibitors (EGFR-TKIs), including erlotinib, gefitinib, icotinib, afatinib, and …
tyrosine kinase inhibitors (EGFR-TKIs), including erlotinib, gefitinib, icotinib, afatinib, and …
Front-line Therapy in Advanced Non–Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis
XY Li, JZ Lin, SH Yu - Clinical Therapeutics, 2020 - Elsevier
Purpose Several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
were firmly established as front-line treatment for non–small cell lung cancer (NSCLC) that …
were firmly established as front-line treatment for non–small cell lung cancer (NSCLC) that …
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus …
Purpose We examined the impact of different epidermal growth factor receptor (EGFR)
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
mutations and clinical characteristics on progression-free survival (PFS) in patients with …